← All trials
NCT04345289
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 20, 2020
- Primary completion
- Jun 15, 2021
- Completion date
- Jun 15, 2021
- First posted
- Apr 14, 2020
- Last posted
- Apr 14, 2020
- Enrollment
- 1500
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of CopenhagenLead sponsor
- University of CopenhagenStudy director
- University of CopenhagenSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.